Clinical Scorecard: Investigation of Risk Factors Linked to Bloodstream Infections from Candida parapsilosis in Children and Factors Influencing Fluconazole Resistance: A 15-Year Retrospective Cohort Study

At a Glance

Key Highlights

• C. parapsilosis is the second most prevalent cause of candidemia in children.
• Fluconazole resistance rates exceed 40-60% in some regions.
• No association between fluconazole resistance and higher mortality rates.
• Identifying clinical risk factors is crucial for guiding empirical therapy.
• Limited pediatric studies on C. parapsilosis highlight the need for further research.

Guideline-Based Recommendations

Diagnosis

• Candidemia is diagnosed through blood culture isolation of fungi in symptomatic patients.

Management

• Empirical antifungal therapy should consider local resistance patterns.

Monitoring & Follow-up

• Monitor for clinical symptoms and laboratory findings post-antifungal treatment.

Risks

• Prior antimicrobial treatment and invasive procedures increase candidemia risk.

Patient & Prescribing Data

Pediatric patients with candidemia, excluding neonates and preterm infants.

Fluconazole exposure defined as 6-12 mg/kg per day within one month of candidemia.

Clinical Best Practices

• Implement stringent infection control measures to manage outbreaks.
• Conduct regular antifungal susceptibility testing to guide treatment decisions.
• Collect comprehensive clinical data for ongoing epidemiological studies.

Related Resources & Content

• Epidemiological trends in candidemia
• Fluconazole resistance in C. parapsilosis
• Clinical and Laboratory Standards Institute guidelines